全文获取类型
| 收费全文 | 29262篇 |
| 免费 | 2478篇 |
| 国内免费 | 92篇 |
专业分类
| 耳鼻咽喉 | 278篇 |
| 儿科学 | 878篇 |
| 妇产科学 | 639篇 |
| 基础医学 | 4326篇 |
| 口腔科学 | 498篇 |
| 临床医学 | 3140篇 |
| 内科学 | 5837篇 |
| 皮肤病学 | 486篇 |
| 神经病学 | 2731篇 |
| 特种医学 | 922篇 |
| 外国民族医学 | 10篇 |
| 外科学 | 3399篇 |
| 综合类 | 518篇 |
| 一般理论 | 16篇 |
| 预防医学 | 2881篇 |
| 眼科学 | 810篇 |
| 药学 | 2231篇 |
| 中国医学 | 41篇 |
| 肿瘤学 | 2191篇 |
出版年
| 2023年 | 138篇 |
| 2022年 | 207篇 |
| 2021年 | 533篇 |
| 2020年 | 390篇 |
| 2019年 | 564篇 |
| 2018年 | 581篇 |
| 2017年 | 451篇 |
| 2016年 | 570篇 |
| 2015年 | 637篇 |
| 2014年 | 903篇 |
| 2013年 | 1225篇 |
| 2012年 | 1884篇 |
| 2011年 | 2095篇 |
| 2010年 | 1047篇 |
| 2009年 | 1037篇 |
| 2008年 | 1685篇 |
| 2007年 | 1878篇 |
| 2006年 | 1771篇 |
| 2005年 | 1769篇 |
| 2004年 | 1647篇 |
| 2003年 | 1388篇 |
| 2002年 | 1376篇 |
| 2001年 | 500篇 |
| 2000年 | 516篇 |
| 1999年 | 546篇 |
| 1998年 | 376篇 |
| 1997年 | 297篇 |
| 1996年 | 289篇 |
| 1995年 | 242篇 |
| 1994年 | 215篇 |
| 1993年 | 181篇 |
| 1992年 | 338篇 |
| 1991年 | 320篇 |
| 1990年 | 303篇 |
| 1989年 | 297篇 |
| 1988年 | 268篇 |
| 1987年 | 249篇 |
| 1986年 | 283篇 |
| 1985年 | 241篇 |
| 1984年 | 212篇 |
| 1983年 | 166篇 |
| 1982年 | 160篇 |
| 1981年 | 126篇 |
| 1980年 | 127篇 |
| 1979年 | 197篇 |
| 1978年 | 143篇 |
| 1977年 | 111篇 |
| 1976年 | 102篇 |
| 1974年 | 116篇 |
| 1973年 | 135篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
Kamolz Lars-Peter Kotzbeck Petra Schintler Michael Spendel Stephan 《European Surgery》2022,54(3):163-169
European Surgery - Large skin defects caused by trauma (e.g., burns) or due to other reasons (e.g., tumor-related skin resections) require sufficient skin replacement. The constant improvement of... 相似文献
2.
3.
4.
5.
A. Cattapan K. Browne D.M. Halperin A. Di Castri P. Fullsack J. Graham J.M. Langley B.A. Taylor S.A. McNeil S.A. Halperin 《Vaccine》2019,37(2):289-295
Introduction/Hypothesis
Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.Methods
An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.Results
A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.Conclusions/Recommendations
Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial. 相似文献6.
7.
Judith Brock Andreas Schmid Thomas Karrasch Petra Pfefferle Jutta Schlegel Inga Busse Annette Hauenschild Barbara Schmidt Maria Koukou Efthymia Arapogianni Andreas Schultz Miriam Thomalla Secil Akinci Johannes Kruse Winfried Padberg Andreas Schffler Jens Albrecht 《Clinical endocrinology》2019,91(3):400-410
8.
9.
